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Reproducibility of the tablet manufacturing process and control of its pharmaceutics properties depends on 
the optimization of formulation aspects and process parameters. Computer simulation such as Design of 
Experiments (DOE) can be used to scale up the production of this formulation, in particular for obtaining 
sustained-release tablets. Bromopride formulations are marketed in the form of extended-release pellets, 
which makes the product more expensive and difficult to manufacture. The aim of this study was to 
formulate new bromopride sustained release formulations as tablets, and to develop mathematical models 
to standardize the scale up of this formulation, controlling weight and hardness of the tablets during 
manufacture according to the USP 34th edition. DOE studies were conducted using Minitab™ software. 
Different excipient combinations were evaluated in order to produce bromopride sustained-release matrix 
tablets. In the scale-up study, data were collected and variations in tableting machine parameters were 
measured. Data were processed by Minitab™ software, generating mathematical equations used for prediction 
of powder compaction behavior, according to the settings of the tableting machine suitable for scale-up 
purposes. Bromopride matrix tablets with appropriate characteristics for sustained release were developed. 
The scale-up of the formulation with the most suitable sustained release profile was established by using 
mathematical models, indicating that the formulation can be a substitute for the pellets currently marketed.
Uniterms: Bromopride/extended-release tablets/preparation. Design of experiments. Extended-release 
tablets/scale up obtention. Direct compression. Tablets/kinetics release.
A reprodutibilidade do processo de fabricação de comprimidos e o controle das suas propriedades 
farmacotécnicas depende da otimização dos aspectos de formulação e dos parâmetros de processo. O 
planejamento de experimentos como o Desenho de Experimentos (DOE) pode ser utilizado para acelerar 
a produção desta formulação, em particular, para a obtenção de comprimidos de liberação prolongada. 
Formulações de bromoprida são comercializadas sob a forma de péletes de liberação prolongada, o que 
torna o produto caro e de difícil fabricação. O objetivo deste estudo foi preparar novas formulações de 
bromoprida de liberação prolongada na forma de comprimidos e desenvolver modelos matemáticos 
visando ao escalonamento destas formulações, controlando o peso e a dureza dos comprimidos durante a 
fabricação, de acordo com a 34ª Edição da USP. Estudos de DOE foram realizados utilizando o software 
Minitab™. Diferentes combinações de excipientes foram avaliadas visando à obtenção dos comprimidos 
de liberação prolongada de bromoprida. No estudo de scale-up, coletaram-se e mediu-se a influência das 
variações nos parâmetros da máquina de compressão. Processaram-se os dados obtidos pelo software 
Minitab ™, gerando equações matemáticas aptas para a previsão do comportamento de compactação do 
pó em escala industrial. Os comprimidos obtidos apresentavam características adequadas em termos de 
liberação sustentada, sendo a cinética de liberação estabelecida utilizando modelos matemáticos, indicando 
que esta formulação pode ser uma substituta aos péletes de bromoprida atualmente comercializados.
Unitermos: Bromoprida/comprimidos de liberação prolongada. Planejamento de experimentos. 
Compressão direta. Comprimidos de liberação prolongada/obtenção em escala aumentada. Comprimidos/
cinética de liberação.
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INTRODUCTION
T h e  i n t e r n a t i o n a l  q u a l i t y  s t a n d a r d s  o f 
pharmaceuticals, as recommended by pharmacopeias 
and regulatory agencies, state the importance of robust 
manufacturing processes, in order to ensure both minimal 
variation between batches and adequate formulation 
development. Oral solid dosage forms must be compliant 
to mass and content uniformity as indicators of robustness, 
where this is even more relevant for sustained-release 
direct compression formulations (Tiwari, Rajabi-
Siahboomi, 2008).
Validation and manufacturing process control are 
therefore key elements in preventing “out-of-specification” 
production. Mass and content uniformity can be indirectly 
evaluated by hardness and weight variations of tablets 
produced during the fabrication process. It is important to 
consider, besides pharmacopeia regulations, the statistical 
process control indicators, as these are associated with 
either formulation or process variations (Gershon, 1991).
Among the  d i fferent  techniques  used  for 
manufacturing tablets, direct compression is the most 
practical and cost-effective (Jivraj, Martini, Thomson, 
2000; McCormick, 2005). For this process, tablets are 
obtained from the mixture of active ingredient and diluents, 
followed by the addition of lubricants, disintegrants and, 
finally, by compression of the final mixture. This method 
may be employed for immediate and extended-release 
forms (Skelly et al., 1993). Comparatively, the direct 
compression method has proven be much simpler, faster 
and cheaper than other techniques for producing sustained-
release solid dosage forms. Thereby is more attractive in 
industrial terms than encapsulation techniques, particularly 
those involving coated pellet or microgranule preparation 
processes, as used to prepare bromopride (BPD) capsules 
(Wertheimer et al., 2005). The development of new 
sustained-release BPD tablets represents an industrial 
solution for cost reduction, leading to a more reproducible 
batch to batch drug release profile.
Mathematical models in compression processes and 
their optimization (Ivic et al., 2010; Yu, 2008; Charoo et al., 
2012) stand out as useful tools for tablets manufacturing 
scale up, particularly for direct compression. Likewise, 
the development of a robust and rational formulation may 
help toward preventing process deviation and ensuring 
dissolution profile reproducibility in sustained-release 
tablet preparation (Bagchi, Li, Plakogiannis, 2012).
Thus, the aim of this study was the development 
and scale-up of new BPD sustained-release tablets 
using hydrophilic matrix by direct compression, 
using mathematical optimization based on Design of 
Experiments (DOE). The proposed formulation is a 
cheaper alternative to the commercial BPD encapsulated 
pellets, which have a higher manufacturing complexity 
and cost.
MATERIAL AND METHODS
Material
The BPD reference chemical substance was obtained 
from Genix (produced as described by ISO guide 34; 
purity 99.95%). Digesan® Retard - RLD (Sanofi-Aventis), 
sustained-release capsules containing coated pellets 
loaded containing 20 mg of BPD, were obtained from the 
market (batches 7051315 and 7051317). Ethyl cellulose 
(EC) 50 mPas was purchased from Sigma-Aldrich (São 
Paulo, Brazil) whereas hydroxypropyl methylcellulose 
(HPMC) 100.000 mPas for small and large-scale batches 
was purchased from Shin-Etsu Chemical (Tokyo, 
Japan). Lactose alpha monohydrate and Viscogel® B8 
(VB8) bentonite modified with octadecylamine salt 
were purchased from Shin-Etsu Chemical Co. Ltd- 
(Tokyo, Japan) and Bentec (Livorno, Italy), respectively. 
Microcrystalline cellulose PH 102 (MC-102) was 
purchased from Blanver (São Paulo, Brazil). Magnesium 
stearate (MS) and talc were supplied by AMC (São Paulo, 
Brazil). Bromopride (active pharmaceutical ingredient) 
was provided by Genix (São Paulo, Brazil). Dissolution 
media were prepared according to the United States 
Pharmacopeia 34 (USP 34, 2011). Water was purified by 
Permution RO 0320 reverse osmosis (Permution, Brazil).
Tablet manufacture
The development of BPD sustained-release tablets 
was performed in low-scale batches with 1.0 kg of 
powder mixture. The sustained-release matrix and BPD 
were mixed in a pilot 6L V mixer for 30 min and then 
the external phase was added and mixed during 5 min 
and compressed using a 9.0-mm biconcave punch. For 
the large-scale batch with the ideal new BPD sustained-
release formulation (200 kg) and for process qualification 
with lactose/cellulose placebo, all components, except 
magnesium stearate, were previously mixed in a stainless 
steel cubic mixer having a 1200 L capacity during 30 min 
at 6 rpm, with rotation direction reversed every 3 min. 
Subsequently, lubricant was added and mixed for 5 min 
and the mixture obtained was directly compressed using 
a Kilian model T400 compressor machine with 55 sets of 
punches, two outputs and a nominal capacity of 680,000 
tablets/h.
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BPD sustained-release tablet formulations
BPD tablets were formulated as an alternative to 
coated pellets marketed in capsules. The tablets were 
prepared by combining several different swelling sustained-
release matrices and 1.0% w/w magnesium stearate added 
as lubricant. The HMPC 100.000 mPas, ethyl cellulose 
50 mPas (Abdel-Rahman, Mahrous, El-Badry, 2009) and 
Viscogel B8 (Dornelas et al., 2008) were tested as sustained-
release matrices at drug:matrix mass ratios of 1:0.5 to 1:3. 
All formulations were prepared in triplicate.
Tablet characterization
The BPD content test was carried out according 
to USP 34 using a Shimadzu UV-160A UV-Vis 
spectrophotometer (Tokyo, Japan). Tablet physical 
properties, such as friability (SOTAX F1 Y-600-01 
friability tester, Switzerland) and hardness (Nova Ética 
298-ATTS hardness tester, Brazil), were evaluated 
according to the USP 34 monograph of BPD tablet 
(USP 34, 2011). The dissolution test was performed on a 
Hanson Research SR8PLUS automatic dissolution system 
(Chatsworth, CA, USA) using previously filtered and 
degassed simulated gastric fluid (SGF) as the dissolution 
media, prepared as recommended by USP 34. Dissolution 
profiles were compared by model-independent and model-
dependent methods (Mourao et al., 2010).
Experimental design
A mathematical model was proposed for describing 
hardness and weight variation (response variables) in the BPD 
tablet production related to process parameter adjustment in 
right side (RS) and left side (LS) of compressor machine. The 
continuous or independent variables selected for test weight 
variation were rotation velocity (rpm), directly related to the 
number of units produced per hour, and the modifications 
of dosing system position (mm), which determines the 
position of lower punches within the matrix at the moment 
of filling. Similarly, minimum distances between upper and 
lower punches and the distance between upper punch top 
and compaction roll at maximum compression point were 
selected as continuous variables for testing the hardness 
variation. Maximum and minimum limits of each parameter 
tested were chosen based on the best conditions obtained 
during the performance qualification of Kilian T400 tableting 
machine using lactose/cellulose placebo. Thus, experimental 
batches were prepared applying a combination of different 
rotation velocities of 400,000 and 100,000 tablets/h; dosing 
system position 4.0 and 6.0 mm; punch distances 0.7 and 2.0 
mm; and upper punch distance 2.2 and 3.0 mm. A factorial 
DOE study with 16 runs (24 factorial model) was developed 
in order to evaluate the robustness of the experimental 
data. Two responses were studied, namely, tablet weight 
and hardness after compaction. Samples of 70 tablets were 
taken per batch for each side of the tablet machine, LS and 
RS (left and right sides). All data (16 batch/tablet machine 
side) were then analyzed using Minitab™ version 7 software 
(Minitab™ Inc., Pennsylvania, US), generating mathematical 
equations which correlated all parameters and settings 
used throughout the tests. For all measurements, variables 
with significant influence on mean weight and hardness 
parameters were considered as those that had p < 0.05. R-Sq 
defined the degree of confidence of the resulting equation, in 
other words, the experiment behavior according to the given 
equation. The correlation model obtained (Poisson, linear 
Pearson or Spearman) shows the influence of the equation 
and, therefore, the variability of weight and hardness, as well 
as the interaction between them.
Statistical analysis
In vitro release kinetics was evaluated by the 
following models (Equations 1 to 5):
Q0 - Qt = K0*t Zero order  (Equation 1)
ln (Q0 – Qt) = K1*t First order  (Equation 2)
Qt = KH*t1/2 Higuchi  (Equation 3)
Qt = Kp*tn               Korsmeyer and Peppas (Equation 4)
W01/3 – Wt1/3 = Ks*t Hixson‐Crowell  (Equation 5)
Where Qt is the concentration of the drug released at time 
t and Q0 is the concentration of drug released at time zero; 
K0, K1 and KH are the coefficients of Zero Order, First 
Order and Higuchi equations, respectively. In equation 4, 
Kp is the constant incorporating structural and geometric 
characteristics of the release device and n is the release 
exponent indicating the release mechanism. In equation 5, 
Ks is a constant incorporating drug surface-volume 
relation and. W0 and Wt are de mass of the drug molecule 
initially and at time t, respectively.
Average data sets of released BPD were assessed 
by variance analysis (One Way ANOVA), with 
a significance level of 0.05 using Statistica 9.0 
software
The applied methods for the in vitro dissolution 
profiles comparison are model-dependent methods, and 
model-independent methods including difference factor, 
f1 (Equation 6), and similarity factor, f2 (Equation 7) 
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(Moore, Flanner, 1996; FDA, 2003; Asare-Addo et al., 
2010; Escudero, Ferrero, Jimenez-Castellanos, 2010).
   (Equation 6)
  (Equation 7)
RESULTS AND DISCUSSION
BPD tablet preparation and evaluation
Different sustained-release matrices were tested in 
order to obtain a new formulation with a suitable BPD 
release profile I. All matrix concentration that do not 
led to a controlled release profile were excluded from 
the study, by listing in Table I only those that showed a 
sustained release profile of BPD. All tablets produced had 
satisfactory friability values and BPD dose values in the 
tested formulations were according to USP 34 monograph 
specifications, 90.0 -110.0% (Table I).
Three different extended-release matrices were 
studied, HPMC, ethyl cellulose and Viscogel® B8 with 
BPD:matrix mass ratio range of 1:1 to 1:3. HPMC and 
ethyl cellulose matrices are usually used in sustained-
release tablet preparation (Velasco et al., 1999; Abdel-
Rahman, Mahrous, El-Badry, 2009). However, Viscogel® 
B8 was not a usual matrix, but had been used previously 
by our research group with good results for production 
of theophylline sustained-release tablets (Dornelas et al., 
2011). A comparable dissolution profile was only obtained 
with the use of HPMC 100000 mPas (Table II and Figure 
1) as the sustained-release matrix. The tablets produced 
with Viscogel® B8 showed good sustained-release 
behavior, but were less efficient than other tested matrices, 
indicating that release from this matrix was dependent on 
drug physicochemical properties and drug loading, being 
more suitable for lipophilic drugs (Korsmeyer et al., 1983; 
Velasco et al., 1999; Dornelas et al., 2011).
For HPMC tablets, dissolution studies showed 
an adequate sustained-release profile of BPD for the 
formulations tested (Figure 1), with a maximum of 
30% of drug released within 20 min using SGF as the 
TABLE II - Percentage of BPD dissolved from different 
sustained-release matrix in SGF after 60 min
SAMPLE % Dissolved in SGF (60 min)
RLD 22.66 ± 3.94
BPD/HPMC
1:1 50.02 ± 3.07
1:2 42.06 ± 2,75
1:3 29.36 ± 2.15
BPD/VCG
1:1 101.49 ± 1.47
1:2 88.12 ± 3.72
1:3 106.64 ± 3.21
BPD/EC
1:1 90.51 ± 0.85
1:2 82.13 ± 1.79
1:3 88.12 ± 6.01
Mean ± RSD.
TABLE I - Composition and properties of different formulations of BPD matrix tablets
Formulations 
Drug:Matrix mass ratio % of BPD Friability %
BPD/HPMC 1:1 96.1 ± 0.27 0.65 ± 0.07
BPD/HPMC 1:2 94.9 ± 0.48 0.48 ± 0.08
BPD/HPMC 1:2.5 94.6 ± 0.39 0.53 ± 0.03
BPD/HPMC 1:3 94.1 ± 0.44 0.45 ± 0.02
BPD/Viscogel®B8 1:1 97.6 ± 0.91 0.55 ± 0.03
BPD/ Viscogel® B8 1:2 98.2 ± 0.17 0.52 ± 0.08
BPD/ Viscogel® B8 1:3 98.3 ± 0.93 0.71 ± 0.07
BPD/ Ethyl cellulose 1:1 100.3 ± 0.85 0.47 ± 0.05
BPD/ Ethyl cellulose 1:2 100.0 ± 0.95 0.58 ± 0.07
BPD/ Ethyl cellulose 1:3 101.7 ± 0.28 0.94 ± 0.02
Mean ± RSD.
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dissolution medium for all tested BPD: matrix mass 
ratios. The BPD:HPMC mass ratio of 1:1 showed a 
drug release of 32.0% in 30 min bearing no similarity to 
Digesan capsules, while the mass ratio of 1:2 released 
only 28.39% at the same time interval. The formulation 
BPD/HPMC 1:3 exhibited an excessive delay in drug 
release, failing to attain 80% drug release by the end of 
the dissolution test (Table II). Compared to the Digesan 
commercial formulation, the BPD/HPMC 1:2 formulation 
showed a very similar drug release profile, demonstrating 
the possibility of using the direct compression production 
method for industrial purposes, with only drug, matrix and 
lubricant in the tablet composition (Figure 1).
The dissolution profile was considered similar only 
for BPD/HPMC 1:2 tablets, where the difference (f1) and 
similarity (f2) factors calculated were 12.08 and 50.65, 
respectively. Korsmeyer-Peppas release kinetics showed 
the best correlation for both formulations in SGF media, 
yielding calculated correlation coefficients of 0.995 for 
Digesan® and 0.990 for BPD/HPMC 1:2. These results 
demonstrate the feasibility of obtaining an alternative 
formulation with greater robustness and lower cost 
compared to the reference product based on encapsulated 
coated pellets.
Design of experiments
After choosing the optimal sustained-release 
formulation, DOE studies were performed using BPD/
HPMC 1:2 powder mixture for scale-up purposes. The 
following BPD tablet parameters were established for 
this study after tablet machine qualification with lactose/
cellulose placebo: cylindrical biplanar morphology; 
FIGURE 1 - Dissolution profiles of bromopride tablets: BPD/
HPMC 1:3; BDP/HPMC 1:2; Reference Label Drug in 0.1 M 
HCl dissolution media.
diameter between 8.80 and 9.20 mm; thickness between 
2.20 and 2.70 mm; hardness between 34 and 103 N; 
average weight 200 mg ± 3%. Four independent variables 
that exert the most impact on weight and hardness for the 
compression process were studied. Rotation velocity and 
dosing system position were studied on the weight variation, 
while distances between two punches and distance between 
upper punch top and compaction roll (compaction roll 
setting) were evaluated on hardness variation. Responses 
were measured at two outputs of the tablet machine feeders, 
to the right and left sides. After data collection, the factorial 
design results was analyzed using the Minitab™ software to 
ascertain the influence of the cited independent variables on 
the studied responses (mean weight and hardness), as well 
as the correlation with equations which determine these 
interdependencies, the degree of interaction, and percentage 
of confidence of measurements. All DOE results obtained 
are given in Tables III to VIII and Figure 2.
It is evident that the dosing system position and 
rotation velocity (rpm) parameters had an influence on 
the weight variation of the tablets, exerting a positive and 
negative effect, respectively. Based on these results, it can 
also be inferred from the overall process that interaction 
among these factors had occurred resulting in a negative 
effect on mean weight (Figure 2A and Figure 2B).
In terms of weight adjustment of the right side of 
the machine, the dosing system position variable showed 
great influence on tablet weight, since the measured values 
had a positive correlation standardized effect and this 
variable had a greater influence on weight than did the 
rotation velocity parameter (rpm). An interaction among 
all parameters in the equation defining weight variation 
behavior was also noted by a negative effect value of 
-2.407 (Table III, IV, Figure 2 A).
On the left side (LS) of the machine, dosing 
system position and rotation velocity variables (rpm) 
displayed a similar influence. The interaction, however, 
between these two parameters is described by a negative 
correlation standardized effect value of -3.118 (Table III 
and Figure 2B). 
The response surface graph of mean weight 
response variable on the right side (Figure 2A) and left 
side (Figure 2B) shows a slight influence of DSP and RV 
interaction. On both sides, the DSP independent variable 
showed greater influence than RV on tablets mean weight, 
increasing response variable from 166 mg to 232 mg by 
a slight DSP changing from 4.0 mm to 6.0 mm, keeping 
constant RV (100,000 tablets/hour) on the right side, for 
example. On the left side of this variation also occurred, 
changing the average weight of 170 mg to 235 mg, proving 
that the left side of the engine showed slight differences 
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TABLE III - Estimated effects and coefficients for mean weight
Effectc Coefd SE Coefe T P
RSf LSg RS LS RS LS RS LS RS LS
Constant ----- ----- 197.495 199.966 0.503 0.9723 392.6 205.67 0.000 0.000
RVa -3.973 -6.688 -1.987 -3.344 0.503 0.9723 - 3.95 -3.44 0.004 0.009
DSPb 62.57 61.595 31.285 30.797 0.503 0.9723 62.19 31.68 0.000 0.000
RV x DSP - 2.407 - 3.118 - 1.203 - 1.559 0.503 0.9723 - 2.39 - 1.6 0.044 0.147
a – RV: rotation velocity; b – DSP: dosing system position; c - Effect: Effect size; d - Coef.:Estimated Coefficients; e - SE Coef.: 
Standard error of estimated coefficient; f-RS: right side; g – LS: left side.
in mechanical adjustment in relation to the right side. 
Furthermore, the independent variable RV caused small 
changes on tablets mean weight of approximately 231 
mg (100,000 tablets/hour) to 225 mg (400,000 tablets/
hour) while DSP independent variable DSP was constant 
at 6.0 mm.
Varying RV independent variable from 100,000 to 
400,000 tablets/hour and keeping DSP constant at 6.0 mm 
on right side there is a variation of 6.38 mg on mean weight 
response variable. In the other hand, on the left side this 
variation is 9.81 mg, showing the higher influence of RV 
on this side, confirming the differences on mechanical 
adjustments between the two sides.
Concerning the studies of variations in hardness, 
similar results were obtained for both outputs sides of the 
machine. For the RS, only the distance between punches 
(MDUL) was detected as an influential parameter, since 
neither compression roll setting (UPCR) nor interaction 
between these variables influenced the hardness outcome. 
The same behavior was found for the LS of the tableting 
machine (Tables IV and VI; Figure 2C and 2D). The 
response variable hardness showed no such interactions 
variables on both sides, showing that the only factor that 
really alters the hardness response variable is MDUL.
It is important to note that the machine settings used 
in this work are made by hand wheels, which are not very 
TABLE IV - Estimated effects and coefficients for hardness
Effectc Coefd SE Coefe T P
RSf LSg RS LS RS LS RS LS RS LS
Constant ----- ----- 58.07 59.38 0.2562 0.4097 226.64 144.92 0.000 0.000
MDULa -86.59 -89.53 -43.30 -44.77 0.2562 0.4097 -168.96 -109.26 0.000 0.000
UPCRb -0.26 -0.01 -0.13 0.000 0.2562 0.4097 -0.50 -0.01 0.630 0.991
MDUL x UPCR 0.43 1.76 0.21 0.880 0.2562 0.4097 0.84 2.15 0.426 0.064
a – MDUL: minimum distances between upper and lower punches; b – UPCR: distance between upper punch top and compaction 
roll at maximum compression; c - Effect: Effect size; d - Coef.: Estimated Coefficients; e - SE Coef.: Standard error of estimated 
coefficient; f – RS: right side; g – LS: left side.
accurate, but that perfectly met the aim of this work. The 
main goal of DOE studies in this work was to understand 
how the response changes in a given direction by adjusting 
the design independent variables.
Taken together, the results obtained from all the 
equations (Table V, TableVI) indicate it is mathematically 
possible to state that experiments will reproduce according 
to the mathematical models in 99% of cases (R-Sq).
After establishing the equations that defined 
tableting machine behavior, based on the BPD/HPMC 1:2 
powder mixture for direct compression tablet manufacture, 
tests were performed with other three batches in order 
to check mean weight and hardness. For this purpose, 
values lying within the limits of the parameters used 
to determine the applicability of these equations were 
adopted in order to prove the robustness of the DOE 
method. Subsequently, some values were randomly 
selected from within each parameter range and used to 
produce a tablet batch, sampling tablets from the tablet 
machine, measuring their average weight and hardness on 
both sides (LS and RS). These experimental values (weight 
of 70 tablets and hardness of 35 tablets, on both sides) 
were compared to those mathematically obtained using 
the equations, in order to verify whether the calculated 
values were within possible limits, considering the 
standard deviation of experimental data. This evaluation 
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FIGURE 2 - Response surface graph of (A) mean weight RS vs DSP vs RV; (B) mean weight LS vs DSP vs RV; (C) hardness RS 
vs MDUL vs UPCR; (D) hardness LS vs MDUL vs UPCR.
TABLE V - Mean weight equations for RS and LS of tablet machine
Machine side Sc R-Sqd R-Sq (adj)e Mean Weight Equation
RSa 1.74259 99.79% 99.72% 197.495 – 1.987 x (RVf) + 31.285 x (DSPg) – 1.203 x (RVf x DSPg)
LSb 3.36809 99.22% 98.93% 199.966 – 3.344 x (RVf) + 30.797 x (DSPg)
a - RS: right side; b - LS: left side; c - S: square root of mean square error; d - R-Sq: estimated R square; e - R-Sq (adj): estimated 
adjusted R square; f - RV: rotation velocity; g - DSP: dosing system position.
TABLE VI - Hardness equations for RS and LS of tablet machine
Machine side Sc R-Sqd R-Sq (adj)e Hardness Equation
RSa 0.88767 99.97% 99.96% 58.07 – 43.30 x (MDULf)
LSb 1.4193 99.93% 99.91% 59.38 – 44.77 x (MDULf)
a - RS: right side; b - LS: left side; c - S: square root of mean square error; d - R-Sq: estimated R square; e - R-Sq (adj): estimated 
adjusted R square; f - MDUL: minimum distances between upper and lower punches.
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was carried out employing the ONE SAMPLE T tool in 
the Minitab™ software package. The results demonstrated 
that, at these two random levels (Table VII, TableVIII), 
statistically relevant mean weight and hardness values 
were obtained that were very close to predicted results, 
thus confirming the predictive capacity of the derived 
equations. Korsmeyer-Peppas release kinetics showed the 
best correlation for the three new batches produced were 
formulations in SGF media, yielding calculated correlation 
coefficients ranging from 0.989 to 0.991, with the amount 
of drug dissolved and dissolution profile showing no 
statistical differences (p>0.05).
CONCLUSIONS
This work allowed the obtention of a robust new 
BPD extended-release formulation for use on a large scale, 
that proved simpler and less expensive than the commercial 
formulation (capsule containing coated pellets, the 
reference product), representing a viable alternative for the 
manufacture of low dosage drugs in sustained-release solid 
oral formulations. The use of Viscogel B8 as the sustained-
release matrix was suggested for lipophilic drugs, but more 
detailed study must be conducted to confirm this proposal. 
Different HPMC concentrations were tested to obtain a 
tablet with appropriate release kinetics, reinforcing the use 
of this excipient as the best matrix for sustained release. In 
the scale-up studies, the BPD/HPMC 1:2 powder mixture 
showed better results when subjected to the compression 
process on a Kilian 400 tableting machine. After analyzing 
the results and comparing them to responses, was observed 
that maximum variation between the theoretical values 
and those obtained on practical tests (residual) did not 
exceed 3.10%, showing that the new formulation obtained 
is reproducible and robust, suitable for the preparation 
of new BPD generic medicines. It is also noted that both 
TABLE VII - Mean weight challenge test
Parameters RSg LSh
DSPa 4.7 mm (-1) 4.7 mm (-1)
RVb 250,000 tablets/h (-1) 250,000 tablets/h (-1)
Equation value 188.109 mg 190.727 mg
Experimental valuec 188.491 ± 2.709 mg 190.906 ± 2.091 mg
95% CId (mg) 187.845 – 189.137 190.407 – 191.404
Te 1.18 0.72
Pf 0.242 0.476
a – RV: rotation velocity; b – DSP: dosing system position; c - Experimental value: average ± SD; d – CI: confidence interval; 
e - T: Indicates direction and degree to which a sample mean difference is distant from null hypothesis (H0) in a range of standard 
deviation units; f - P: p-value is probability of obtaining a statistic test at least as extreme as that observed, assuming null hypothesis 
is true; g – RS: right side; h – LS: left side.
TABLE VIII - Hardness challenge test
Parameters RSg LSh
MDULa 1.3 mm (-1) 1.3 mm (-1)
UPCRb 2.4 mm (-1) 2.4 mm (-1)
Equation value 61.101 N 62.513 N
Experimental valuec 60.4677 ± 4.26 N 64.058 ± 4.66 N
95% CId (N) 59.0043 – 61.9311 62.4588 – 65.6580
Te -0.88 1.96
Pf 0.385 0.058
a – MDUL: minimum distances between upper and lower punches; b – UPCR: distance between upper punch top and compaction 
roll at maximum compression; c - Experimental value: average ± SD; d – CI: confidence interval; e -T: Indicates direction and 
degree to which a sample mean difference is distant from null hypothesis (H0) in a range of standard deviation units; f - P: p-value 
is probability of obtaining a statistic test at least as extreme as that observed, assuming null hypothesis is true; g – RS: right side; 
h – LS: left side.
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sides of the compressor machine presented negative 
influence by DSP and RV interaction. Left side presented 
higher influence of RV factor than right side, confirming 
mechanical differences on machine adjustment. Hardness 
was not influenced by independent variables interactions 
on both sides, which showed similar profiles in hardness 
changes.
This study applies to several purposes, among which 
can be highlighted: The rapid adjustment of compressor 
machine, productivity increase, reduction of waste 
production; rational use of raw materials, reduction of 
environmental impacts by destruction of production waste.
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